Q-omics provides the consensus-scored CKMT1B profile across patient tissues and cancer cell-line models. CKMT1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CKMT1B is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CKMT1B RNA expression shows 20,326 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where CKMT1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKMT1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKMT1B survival associations across molecular data types. CKMT1B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKMT1B RNA expression–survival associations across cancer types. High CKMT1B expression shows unfavorable associations in UCEC and UCS, but favorable associations in KIRP, LGG, LUSC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CKMT1B RNA expression.
This table summarizes CKMT1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CKMT1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKMT1B shows lower tumor expression in KIRC and COAD and higher tumor expression in LUAD, LUSC, BLCA and KICH. The KIRC box plot shows higher CKMT1B RNA expression in normal versus tumor tissue (log2 FC = −1.330, t-test p < 0.001).
This table shows molecular features associated with CKMT1B in patient tissues and cancer cell lines. In patient samples, CKMT1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CKMT1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
